Business
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration with Verix, a leader in AI-powered commercial optimization technology for the life sciences sector. Citius Oncology's commercial team intends to further leverage Verix's innovative Tovana platform
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"CRANFORD, N.J., Nov. 21, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration with Verix, a leader in AI-powered commercial optimization technology for the life sciences sector. Citius Oncology's commercial team intends to further leverage Verix's innovative Tovana platform to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.","length":919,"tagName":"p"},{"type":"text","content":"Verix's Tovana platform integrates advanced analytics, real-world claims data, and machine learning to help inform Citius Oncology's commercial strategy and enable real-time field execution. The platform refines targeting over time and supports data-driven decisions, allowing the Citius Oncology commercial team to embed predictive intelligence into sales and marketing plans, and to prioritize engagement with high-impact healthcare providers (HCPs). Using company-defined criteria, the system identifies patterns in treatment and diagnosis, enabling Citius Oncology's commercial team to promptly engage prescribers whose patients may benefit from LYMPHIR.","length":670,"tagName":"p"},{"type":"text","content":""We are committed to leveraging leading-edge technologies to maximize the commercial impact of LYMPHIR and look forward to using this innovative AI platform to amplify the precision and impact of our experienced commercial and marketing teams," stated Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. "Through our collaboration with Verix, we are able to enhance our salesforce's experienc...